- Home
- ATEX vs PRTA Comparison
ATEX vs PRTA Comparison
Compare ATEX & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATEX
- PRTA
- Stock Information
- Founded
- ATEX 1997
- PRTA 2012
- Country
- ATEX United States
- PRTA Ireland
- Employees
- ATEX N/A
- PRTA N/A
- Industry
- ATEX Telecommunications Equipment
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- ATEX Telecommunications
- PRTA Health Care
- Exchange
- ATEX Nasdaq
- PRTA Nasdaq
- Market Cap
- ATEX 419.2M
- PRTA 472.1M
- IPO Year
- ATEX N/A
- PRTA N/A
- Fundamental
- Price
- ATEX $23.74
- PRTA $8.20
- Analyst Decision
- ATEX Buy
- PRTA Buy
- Analyst Count
- ATEX 1
- PRTA 10
- Target Price
- ATEX $67.00
- PRTA $14.86
- AVG Volume (30 Days)
- ATEX 219.2K
- PRTA 1.2M
- Earning Date
- ATEX 08-12-2025
- PRTA 08-04-2025
- Dividend Yield
- ATEX N/A
- PRTA N/A
- EPS Growth
- ATEX N/A
- PRTA N/A
- EPS
- ATEX 1.58
- PRTA N/A
- Revenue
- ATEX $5,924,000.00
- PRTA $10,341,000.00
- Revenue This Year
- ATEX N/A
- PRTA N/A
- Revenue Next Year
- ATEX $7.88
- PRTA $389.77
- P/E Ratio
- ATEX $14.86
- PRTA N/A
- Revenue Growth
- ATEX 15.97
- PRTA N/A
- 52 Week Low
- ATEX $20.61
- PRTA $4.32
- 52 Week High
- ATEX $42.91
- PRTA $22.83
- Technical
- Relative Strength Index (RSI)
- ATEX 59.24
- PRTA 58.73
- Support Level
- ATEX $20.90
- PRTA $8.05
- Resistance Level
- ATEX $24.35
- PRTA $8.73
- Average True Range (ATR)
- ATEX 1.13
- PRTA 0.38
- MACD
- ATEX 0.33
- PRTA -0.05
- Stochastic Oscillator
- ATEX 83.22
- PRTA 47.62
About ATEX Anterix Inc.
Anterix Inc is a United States-based company engaged in delivering broadband needed to modernize infrastructure for energy, transportation, logistics, and other industries. The company offers Private LTE for utilities which help to automate processes, monitor environmental conditions, enable artificial intelligence, and drive productivity.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.